Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma Allogeneic hematopoietic stem cell transplantation from related or unrelated donor has become a standard treatment for many patients with hematological malignancies, but the role of this treatment approach in the treatment of multiple myeloma remains controversial, as high risk of relapse remains a major concern. 1 In acute leukemias, especially acute myeloid leukemias, alloreactive donor-derived natural killer cells (NK cells) have been correlated with an improved survival, especially after T-cell-depleted transplant procedures such as haploidentical stem cell transplantation. 2 Small reports after allogeneic stem cell transplantation for multiple myeloma as well as pre-clinical models showed that alloreactive NK cells might have a role regarding cytotoxicity and relapse prevention in multiple myeloma. 3 The NK cell function is determined by several receptor families including activating and inhibitory killer cell immunoglobulin-like receptors (KIRs). For the majority, especially for the active KIRs, the correspondent ligands are unknown. Nevertheless, there is an interaction between inhibitory KIRs on donor-derived NK cells and human leukocyte antigen (HLA) class-I molecules on the recipient to determine alloreactivities on healthy and malignant cells. All HLA C allotypes have either C1 epitope, a ligand for KIR2DL2/3, or the C2 epitope, which is a ligand for KIR2DL1. Additionally, the HLA B allotypes have either BW4 or BW6 epitope, but only the BW4 epitope is a ligand for the KIR3DL1. Therefore, in allogeneic stem cell transplantation setting, it is assumed that donor NK cells attack recipient cells by recognizing HLA class-I ligands, which are not sufficiently engaged by their inhibitory receptors. As the KIR genes are located on chromosome 19, they are segregated independently from HLA, which implies that especially after unrelated allogeneic stem cell transplantation and also after HLA-identical matched transplantation, KIR genes do not consequently match between donors and recipients. The effect of KIRs on outcome after allogeneic stem cell transplantation has been investigated by several models. The KIR-ligand mismatch model that is based on the 'missing self theory', which explains alloreactive NK cells and is based only on HLA typing (ligand-ligand model), has not shown conclusive results. The missing KIR-ligand model (or receptor-ligand model) was proposed if the recipients are homozygous for HLA Cw group I, II or BW6 and the donor KIR genotyping included at least one KIR that lacks the corresponding ligand or the recipient (donor: 2DL2/3 and recipient lacks Cw group I; donor 2DL1 and recipient lacks Cw group II or donor 3DL1 and recipient lacks BW4 (which leads to NK alloreactive cell lysis because of inhibitory KIRs lacking corresponding HLA ligand, class-I ligand)), although all these models could not show conclusive results after allogeneic stem cell transplantation. A more attractive model is to distinguish the diverse KIR haplotypes into two biological distinguished groupsFgroup A and B. The B haplotype has more activating receptor genes (S1) than A. B haplotype in the donor (BB or B/X) promotes disease-free survival in acute myeloid leukemia (AML), most often regardless of patient haplotype. 4, 5 The role of NK alloreactivity and of donor KIR genotype in myeloma is unclear. Here we studied the impact of donor KIR genotyping, KIR-ligand mismatch and KIR haplotypes on clinical outcome in patients with multiple myeloma who underwent allogeneic stem cell transplantation.
From 1997 until 2008, a total of 118 patients with multiple myeloma who received allogeneic stem cell transplantation at the University Medical Center Hamburg were included. Patients were treated either in an auto-allo tandem protocol (n ¼ 65; NCT 00777998) or in a protocol for patients with relapse after autologous stem cell transplantation (n ¼ 46; NCT 00781170) or were refractory to conventional therapy (n ¼ 7; see Table 1 ).
HLA A, B, C, DRB1 and DQB1 alleles and 14 KIR genes were typed with sequence-specific oligonucleotide probes with the help of the PCR-rSSO (Luminex, OneLambda, BmT, GmbH, Meerbusch, Germany) as described elsewhere. 4 The homozygous haplotypes as defined by Uhrberg et al. 6 were used as an input matrix together with the KIR typing results for the presence or absence of 14 KIR genes to calculate the most likely underlying homozygous or heterozygous haplotypes.
The cumulative incidence (CI) of treatment-related mortality (TRM) of the whole study group at 1 year was 27% (95% CI: 19-35%). Donor haplotype Bx resulted in a trend for lower TRM (23 vs 36%; P ¼ 0.1). In a multivariate Cox model, significant risk factors for high TRM were female sex of the donor (HR: 2.93, 95% CI: 1.49-5.78, P ¼ 0.002) and patient's age as continuous variable (HR: 1.04, 95% CI: 1.00-1.08, P ¼ 0.03; Table 2 ).
The cumulative incidence of relapse at 5 years was 45% (95% CI: 35-55%). Donor KIR haplotype Bx resulted in a trend for lower relapse rate (43 vs 48%, P ¼ 0.4), but in the subgroup of fully HLA-matched donor KIR haplotype AA resulted in a significant higher risk of relapse at 1 year compared with transplantation from donor type KIR Bx (46 vs 17%, P ¼ 0.005). Table 1 Patients' characteristics (n ¼ 118)
CMV-serostatus Positive 71 Negative 47
Conditioning regimen
Reduced intensity n ¼ 106 Standard conditioning n ¼ 12 
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We could also find a lower risk of relapse (22 vs 50%) but the number of patients with KIR-ligand mismatch in GvH direction was too small (n ¼ 9) to reach statistical significance. In a multivariate analysis, female sex of the donor (HR: 0.52, 95% CI: 0.29-0.94, P ¼ 0.03) and del(13q14) (HR: 2.70, 95% CI: 1.43-5.11, P ¼ 0.002) were significant factors for risk of relapse ( Table 2) . The estimated 5-year progression-free survival of the study population was 25% (95% CI: 17-33%) and significantly better for patients with donor KIR haplotype Bx than AA (30 vs 14%, P ¼ 0.009). The survival benefit for KIR haplotype Bx was mainly seen in HLA-matched patients (4-year DFS: 39 vs 18%, P ¼ 0.005), while in HLA-mismatch transplantation the difference did not reach statistical significance (26 vs 18%, P ¼ 0.5; see Figure 1 ). In a multivariate Cox model female donor sex (HR: 1.62, 95% CI: 1.06-2.48, P ¼ 0.03), KIR donor haplotype AA (HR: 1.82, 95% CI: 1.17-2.83, P ¼ 0.008), unrelated donor (HR: 1.83, 95% CI: 1.13-2.96, P ¼ 0.02) and patient's age (HR: 1.03, 95% CI: 1.01-1.06, P ¼ 0.008) were independent significant factors for worse progression-free survival ( Table 2) .
The estimated 5-year overall survival was 44% (95% CI 34-54%) and better for patients transplanted from a donor with KIR haplotype Bx than AA (49 vs 36%, P ¼ 0.08). In a multivariate analysis donor female sex (HR: 1.67, 95% CI: 1.03-2.71, P ¼ 0.04), donor haplotype AA (HR: 1.69, 95% CI: 1.02-2.81, P ¼ 0.04) and chemorefractory disease (HR: 1.76, 95% CI: 1.05-2.95, P ¼ 0.03) were independent significant factors for decreased survival. In a detailed analysis of impact of single KIR genes we could not find any benefit for survival of any donor KIR gene, nor did we find any association with the number of activating KIR genes.
As female donor sex and donor KIR haplotype AA influenced independently overall survival after transplantation we simulated different donor selection. Three-year survival is worse with female donor harboring KIR haplotype AA (31%), followed by female donor harboring Bx KIR haplotype (42%) and male donor with KIR haplotype AA (50%), while patients transplanted with male donor harboring haplotype Bx resulted in 3-year survival of 67% (P ¼ 0.05; see Figure 2 ).
More recent studies on KIR genotype of the donor in allogeneic stem cell transplantation for leukemia patients, suggest a survival benefit for those patients who received stem cell graft from a donor carrying haplotype BB or BA (Bx). 5 In this trial including 448 patients with AML who received unrelated stem cell graft after myeloablative conditioning, patients receiving grafts from donors with KIR haplotype Bx had an improved risk of relapse-free survival of 30%. A subsequent analysis including 1409 unrelated donors confirmed the beneficial effect of donor KIR haplotype Bx in AML, but not in acute lymphoblastic leukemia. In our trial, we found a significant benefit for disease-free as well as for overall survival for myeloma patients who received graft from donor with KIR haplotype B. This benefit was more obvious in patients receiving transplant from HLA-matched rather than from an HLAmismatched donor. This is in accordance to the recent observation in AML showing advantage for donor KIR haplotype Bx only in HLA-identical sibling transplantation, while the disadvantage of HLA mismatching could not be overcome by donor KIR haplotype Bx. 5 The effect of KIR haplotype B is due to a non-significant trend in relapse as well as non-relapse mortality. We did not find an association between donor KIR genes and occurrence of acute or chronic graft-versus-host disease. The effect of single-donor KIR gene remains controversial. In some studies, presence of 3DS1 in donors was protective against the development of graft-versus-host disease. 7 In our study, we could not detect an association of outcome with any particular Bx haplotype-defined KIR gene. Furthermore, we found a significant effect on outcome for female donor sex. This effect of female donor sex in survival is mainly because of higher non-relapse mortality. Even if the risk of relapse is reduced in female donor, the effect of higher non-relapse mortality offset this advantage resulting in worse overall survival. This observation confirmed the deleterious effect of female donor sex in myeloma patients reported by the European 
Group for Blood and Marrow Transplantation. 8 In this trial female donor sex not only resulted in higher treatment-related mortality but also in a lower risk of relapse, indicating a sexspecific graft-versus-myeloma effect. As KIR haplotype and donor sex are a factor which might be potentially be influenced by careful donor selection we simulated a donor selection model for KIR haplotype and donor sex, which clearly favors a male KIR haplotype B donor to all other combinations with an improved survival of more than 30% in favor of female donors with KIR haplotype AA. Although the underlying mechanism remains uncertain, this first study in myeloma patients demonstrates a significant benefit of NK cell alloreactivity in outcome after allogeneic stem cell transplantation. If available, a male donor harboring KIR haplotype B should be a donor of choice for myeloma patients undergoing allogeneic stem cell transplantation.
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Hospital Hamburg-Eppendorf, Hamburg, Germany; Acquired somatic mutations affecting TET oncogene family number 2 (TET2), isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and additional sex combs-like 1 (ASXL1) have been recently described in BCR-ABL-negative neoplasm, myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), MDS/MPN and acute myeloid leukemias (AMLs), including transformations of MDS or MPN. 1 TET2 mutations are diverse (frameshift, nonsense and missense mutations) and do not cluster in a particular region of the protein. In contrast, mutations affecting IDH1/2 and ASXL1 are found in restricted regions. 2, 3 None of these gene alterations are disease-specific and their incidence ranges from rare to 40%.
1 Another important observation from recent related studies is that these mutations can coexist with other pathogenetically relevant mutations including JAK2V617F, sometimes before or emerging in a subclone. 4 Therefore, and especially in view of the occurrence of these mutations across varying molecular profiles, their contribution to disease initiation, clonal evolution or blastic transformation is not clear. Also, the possibility of independently emerging multiple abnormal clones rather than monoclonal myeloproliferation is raised. In chronic myeloid leukemia (CML), BCR-ABL fusion is known to be the driver mutation. However, leukemogenesis is a complex process, and genomic heterogeneity of the chronic phase (CP) of the disease has been reported. 5 This intrinsic heterogeneity at the molecular level could support a causative link with the varying response to treatment and disease progression. Furthermore, we still do not know for sure whether the BCR-ABL fusion is really the initiating lesion. In order to describe TET2, IDH1, IDH2 and ASXL1 mutation prevalence, to investigate whether these defects could represent an important event in CML initiation, and to define the relationships between acquisition of these mutations and CML transformation and/or imatinib (IM) resistance, here we report on a mutation analysis done on paired samples from CML at diagnosis (untreated), time of IM response and, when available, complete cytogenetic response (CCR) in 91 CML patients treated with IM as first lineFmost of them from the French SPIRIT trialFand presenting five profiles of IM response at the time of analysis: (1) 25 had CCR and major molecular response (MMR) at 12 months of IM; (2) 11 were in CCR but showed a Ph negative (PhÀ) clonal evolution 12-24 months after IM (median 12 months); (3) 20 were in partial cytogenetic response (4 minor and 16 major), 3 of them with additional cytogenetic abnormalities (ÀY, þ 8, þ 8) 18 months after IM and referred as primary resistant (R1); (4) 20 were in acute transformation (14 myeloid, 6 lymphoid) 4-72 months after onset of IM (median 12 months); and (5) 15 referred as secondary IM-resistant (R2) had relapse in CP (4 molecular relapse, 6 loss of CCR and 5 hematologic relapse). Sokal scores were homogeneously distributed among the five groups except for group 2, which did not have higher scores. Except for group 1, BCR-ABL residual disease evaluated by RQ-PCR remained high (median value 0.09%, according to the International Scale (IS)).
Genomic DNA was extracted from bone marrow or peripheral blood mononuclear cells at diagnosis or at time of IM response using standard procedures. The search for mutation was performed by sequencing the entire TET2 coding gene (11 exons), the IDH1 and IDH2 exon 4 and the ASXL1 exon 12. For the TET2 p.P1617fs (C4851del) mutation, ASO-PCR detection was performed on DNA obtained from the healthy donor or unique patient number (UPN) 2 at the time of myeloid transformation or at diagnosis. For the common p.G646WfsX12 (c.1934dupG), five repeated and independent sequencing analyses confirmed the somatic status of this specific variation, as it was always found in patients' samples but was not found among the 50 healthy DNA samples from donors.
As presented in Table 1 , we identified TET2 2 'stop' mutations for UPN 1 (A2079del-p.K700fs and T4893A-p.Y1631X, both also detected at diagnosis) and one 'stop' mutation for UPN 2 (C4851del-p.P1617fs). For UPN 2, the mutation was not
